Posterior wall isolation in persistent atrial fibrillation. Long-term outcomes of a repeat procedure strategy.

Continuous rhythm monitoring Long-term outcomes Mandated repeat ablation Persistent atrial fibrillation Posterior wall

Journal

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 12 09 2022
accepted: 17 10 2022
medline: 12 5 2023
pubmed: 4 11 2022
entrez: 3 11 2022
Statut: ppublish

Résumé

Posterior wall isolation (PWI) added to pulmonary vein isolation (PVI) is increasingly used in ablation for persistent atrial fibrillation (PeAF) despite limited evidence of clinical benefit. We investigated the 5-year outcomes of a PVI + PWI ablation strategy with mandatory repeat procedures in PeAF. Twenty-four patients with PeAF participated in this single-arm prospective study and underwent radiofrequency ablation (RFA) with wide area circumferential ablation (WACA), roof, and inferior lines for PVI + PWI which was reinforced if required during mandated repeat procedures after 6 months. Then, patients were followed for 60 months using continuous heart rhythm monitoring by implanted cardiac monitors (ICM) and atrial fibrillation effect on quality-of-life scoring (AFEQT; range: 20-100 points) for the initial 30 months. ICM-verified cumulated AF recurrence was 54% after 30 months but the ensuing AF burden was only median 0‰ [0 to 4.8‰] overall and 1‰ [0 to 8 ‰] among patients with any recurrence. AFEQT scores increased from baseline 60 points [48 to 72] to 93 points [84 to 96] at repeat procedures P < 0.0001 and further to 96 points [93 to 99] P = 0.03 after 30 months. After 60 months, at least one episode of AF had been documented in 63% and two patients (8%) were in permanent AF. Reinforced PVI + PWI was associated with low long-term AF burden and corresponding improvements in quality-of-life. Reinforced (or durable) PVI + PWI appears to be a promising strategy to treat PeAF. ClinicalTrials.gov. Identifier: NCT05045131.

Sections du résumé

BACKGROUND BACKGROUND
Posterior wall isolation (PWI) added to pulmonary vein isolation (PVI) is increasingly used in ablation for persistent atrial fibrillation (PeAF) despite limited evidence of clinical benefit. We investigated the 5-year outcomes of a PVI + PWI ablation strategy with mandatory repeat procedures in PeAF.
METHODS METHODS
Twenty-four patients with PeAF participated in this single-arm prospective study and underwent radiofrequency ablation (RFA) with wide area circumferential ablation (WACA), roof, and inferior lines for PVI + PWI which was reinforced if required during mandated repeat procedures after 6 months. Then, patients were followed for 60 months using continuous heart rhythm monitoring by implanted cardiac monitors (ICM) and atrial fibrillation effect on quality-of-life scoring (AFEQT; range: 20-100 points) for the initial 30 months.
RESULTS RESULTS
ICM-verified cumulated AF recurrence was 54% after 30 months but the ensuing AF burden was only median 0‰ [0 to 4.8‰] overall and 1‰ [0 to 8 ‰] among patients with any recurrence. AFEQT scores increased from baseline 60 points [48 to 72] to 93 points [84 to 96] at repeat procedures P < 0.0001 and further to 96 points [93 to 99] P = 0.03 after 30 months. After 60 months, at least one episode of AF had been documented in 63% and two patients (8%) were in permanent AF.
CONCLUSION CONCLUSIONS
Reinforced PVI + PWI was associated with low long-term AF burden and corresponding improvements in quality-of-life. Reinforced (or durable) PVI + PWI appears to be a promising strategy to treat PeAF.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov. Identifier: NCT05045131.

Identifiants

pubmed: 36327059
doi: 10.1007/s10840-022-01402-x
pii: 10.1007/s10840-022-01402-x
doi:

Banques de données

ClinicalTrials.gov
['NCT05045131']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

971-979

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Bai R, Di BL, Mohanty P, et al. Proven isolation of the pulmonary vein antrum with or without left atrial posterior wall isolation in patients with persistent atrial fibrillation. Heart Rhythm. 2016;13(1547–5271 (Linking)):132–140. https://doi.org/10.1016/j.hrthm.2015.08.019
Barbhaiya CR, Knotts RJ, Beccarino N, et al. Multiple procedure outcomes for nonparoxysmal atrial fibrillation: left atrial posterior wall isolation versus stepwise ablation. J Cardiovasc Electrophysiol. 2020;31(12):3117–23. https://doi.org/10.1111/jce.14771 .
doi: 10.1111/jce.14771 pubmed: 33022816
Jiang X, Liao J, Ling Z, et al. Adjunctive left atrial posterior wall isolation in treating atrial fibrillation. JACC: Clinical Electrophysiol. 2022;8(5):605–18. https://doi.org/10.1016/j.jacep.2022.02.001 .
doi: 10.1016/j.jacep.2022.02.001
Worck R, Sørensen SK, Johannessen A, Ruwald M, Haugdal M, Hansen J. Posterior wall isolation in persistent atrial fibrillation feasibility, safety, durability, and efficacy. J Cardiovasc Electrophysiol. 2022;33(8):1667–74. https://doi.org/10.1111/jce.15556 .
doi: 10.1111/jce.15556 pubmed: 35598313 pmcid: 9543717
Verma A (2022) Strategies for catheter ablation of persistent atrial fibrillation: a randomized, comparative study. Clin Trials.gov; 2022. Accessed 4 Jul 2022. https://clinicaltrials.gov/ct2/show/NCT04428944
Chieng D, Sugumar H, Ling LH, et al. Catheter ablation for persistent atrial fibrillation: a multicenter randomized trial of pulmonary vein isolation (PVI) versus PVI with posterior left atrial wall isolation (PWI) - The CAPLA study. Am Heart J. 2022;243:210–20. https://doi.org/10.1016/j.ahj.2021.09.015 .
doi: 10.1016/j.ahj.2021.09.015 pubmed: 34619143
Spertus J, Dorian P, Bubien R, et al. Development and validation of the atrial fibrillation effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011;4(1):15–25. https://doi.org/10.1161/CIRCEP.110.958033 .
doi: 10.1161/CIRCEP.110.958033 pubmed: 21160035
Andrade JG, Deyell MW, Verma A, Macle L, Khairy P. The cryoballoon vs irrigated radiofrequency catheter ablation (CIRCA-DOSE) study results in context. Arrhythm Electrophysiol Rev. 2020;9(1):34–9. https://doi.org/10.15420/aer.2019.13 .
doi: 10.15420/aer.2019.13 pubmed: 32637118 pmcid: 7330729
Sørensen SK, Johannessen A, Worck R, Hansen ML, Hansen J. Radiofrequency versus cryoballoon catheter ablation for paroxysmal atrial fibrillation: durability of pulmonary vein isolation and effect on atrial fibrillation burden: the RACE-AF randomized controlled trial. Circ Arrhythm Electrophysiol. 2021;14(5):e009573. https://doi.org/10.1161/CIRCEP.120.009573 .
doi: 10.1161/CIRCEP.120.009573 pubmed: 33835823 pmcid: 8136462
Sulke N, Dulai R, Freemantle N, et al. Long term outcomes of percutaneous atrial fibrillation ablation in patients with continuous monitoring. Pacing Clin Electrophysiol. 2021;44(7):1176–84. https://doi.org/10.1111/pace.14282 .
doi: 10.1111/pace.14282 pubmed: 34028066
Valderrábano M, Peterson LE, Swarup V, et al. Effect of catheter ablation with vein of Marshall ethanol infusion vs catheter ablation alone on persistent atrial fibrillation: the VENUS randomized clinical trial. JAMA. 2020;324(16):1620–8. https://doi.org/10.1001/jama.2020.16195 .
doi: 10.1001/jama.2020.16195 pubmed: 33107945
Reddy VY, Anic A, Koruth J, et al. Pulsed field ablation in patients with persistent atrial fibrillation. J Am Coll Cardiol. 2020;76(9):1068–80. https://doi.org/10.1016/j.jacc.2020.07.007 .
doi: 10.1016/j.jacc.2020.07.007 pubmed: 32854842
Gupta D, Vijgen J, Potter TD, et al. Quality of life and healthcare utilisation improvements after atrial fibrillation ablation. Heart. 2021;107(16):1296–302. https://doi.org/10.1136/heartjnl-2020-318676 .
doi: 10.1136/heartjnl-2020-318676 pubmed: 33952593
Wechselberger S, Kronborg M, Huo Y, et al. Continuous monitoring after atrial fibrillation ablation: the LINQ AF study. Europace. 2018;20(FI_3):f312–20. https://doi.org/10.1093/europace/euy038 .
doi: 10.1093/europace/euy038 pubmed: 29688326 pmcid: 6277150
Diederichsen SZ, Haugan KJ, Kronborg C, et al. Comprehensive evaluation of rhythm monitoring strategies in screening for atrial fibrillation: insights from patients at risk monitored long term with an implantable loop recorder. Circulation. 2020;141(19):1510–22. https://doi.org/10.1161/CIRCULATIONAHA.119.044407 .
doi: 10.1161/CIRCULATIONAHA.119.044407 pubmed: 32114796
Balabanski T, Brugada J, Arbelo E, et al. Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. EP Europace. 2019;21(12):1802–8. https://doi.org/10.1093/europace/euz216 .
doi: 10.1093/europace/euz216
Sanders P, Pürerfellner H, Pokushalov E, et al. Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: results from the Reveal LINQ Usability Study. Heart Rhythm. 2016;13(7):1425–30. https://doi.org/10.1016/j.hrthm.2016.03.005 .
doi: 10.1016/j.hrthm.2016.03.005 pubmed: 26961298
Pothineni NVK, Amankwah N, Santangeli P, et al. Continuous rhythm monitoring-guided anticoagulation after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2021;32(2):345–53. https://doi.org/10.1111/jce.14864 .
doi: 10.1111/jce.14864 pubmed: 33382500
Sawhney N, Anousheh R, Chen W, Feld GK. Circumferential pulmonary vein ablation with additional linear ablation results in an increased incidence of left atrial flutter compared with segmental pulmonary vein isolation as an initial approach to ablation of paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(3):243–8. https://doi.org/10.1161/CIRCEP.109.924878 .
doi: 10.1161/CIRCEP.109.924878 pubmed: 20339034
Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20(1):e1–160. https://doi.org/10.1093/europace/eux274 .
doi: 10.1093/europace/eux274 pubmed: 29016840
Pambrun T, Duchateau J, Delgove A, et al. Epicardial course of the septopulmonary bundle: Anatomical considerations and clinical implications for roof line completion. Heart Rhythm. 2021;18(3):349–57. https://doi.org/10.1016/j.hrthm.2020.11.008 .
doi: 10.1016/j.hrthm.2020.11.008 pubmed: 33188900
Takigawa M, Derval N, Frontera A, et al. Revisiting anatomic macroreentrant tachycardia after atrial fibrillation ablation using ultrahigh-resolution mapping: Implications for ablation. Heart Rhythm. 2018;15(3):326–33. https://doi.org/10.1016/j.hrthm.2017.10.029 .
doi: 10.1016/j.hrthm.2017.10.029 pubmed: 29081399
Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: The Danish National Prescription Registry. Int J Epidemiol. 2017;46(3):798–798f. https://doi.org/10.1093/ije/dyw213 .
doi: 10.1093/ije/dyw213 pubmed: 27789670

Auteurs

René Worck (R)

Department of Cardiology, Copenhagen University Hospital Gentofte, Gentofte Hospitalsvej 1, DK-2900, Hellerup, Denmark. rwor0003@regionh.dk.

Samuel K Sørensen (SK)

Department of Cardiology, Copenhagen University Hospital Gentofte, Gentofte Hospitalsvej 1, DK-2900, Hellerup, Denmark.

Arne Johannessen (A)

Department of Cardiology, Copenhagen University Hospital Gentofte, Gentofte Hospitalsvej 1, DK-2900, Hellerup, Denmark.

Martin H Ruwald (MH)

Department of Cardiology, Copenhagen University Hospital Gentofte, Gentofte Hospitalsvej 1, DK-2900, Hellerup, Denmark.

Morten Lock Hansen (ML)

Department of Cardiology, Copenhagen University Hospital Gentofte, Gentofte Hospitalsvej 1, DK-2900, Hellerup, Denmark.

Martin Haugdal (M)

Department of Cardiology, Copenhagen University Hospital Gentofte, Gentofte Hospitalsvej 1, DK-2900, Hellerup, Denmark.

Jim Hansen (J)

Department of Cardiology, Copenhagen University Hospital Gentofte, Gentofte Hospitalsvej 1, DK-2900, Hellerup, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH